Abstract: The present invention relates to the Grb3-3 protein, nucleotide sequence encoding this protein, and variants thereof, such as antisense sequences. The invention further relates to vectors comprising these sequences and to methods for inducing cell death.

Abstract: Application of riluzole or its pharmaceutically acceptable salts in the treatment of neurological lesions related to traumatic injuries, especially spinal, cranial or cranial-spinal injuries.

Abstract: The present invention relates to a modified yeast wherein at least two of the genes controlling the cellular permeability of said yeast are modified, said modifications having an additive or synergic effect. It also relates to a method for the preparation of said yeast as well as to its utilizations.

Abstract: New taxoids of general formula (I), their preparation, and pharmaceutical compounds containing them. ##STR1## In general formula (I), for example, Ar represents an aryl radical,R represents an alkoxyacetyl radical,R.sub.1 represents a benzoyl radical or a radical of formula R.sub.2 --O--CO-- in which R.sub.2 represents an optionally substituted alkyl radical, an alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical.The new products of general formula (I) have a remarkable antitumor activity.

Abstract: Method for the preparation of 1,3-oxazolidin 5-carboxylic acid having the general formula (I) ##STR1## from a product having the general formula (II) ##STR2## In the general formulas (I) and (II), Ar is an aryl radical, R.sub.1 is a benzoyl radical or a radical R.sub.2 --O--CO-- wherein R.sub.2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl radical, Ph is an optionally substituted phenyl radical, X is the residue of an optically active organic base or an alkoxy radical optionally substituted by a phenyl radical. The acids of formulas (I) and (II) are particularly useful in preparing taxol, Taxotere or analogs thereof which have remarkable antitumor and antileukemia properties.

Abstract: Pharmaceutical compositions containing, as the active principle, compounds of formula (I): ##STR1## wherein R, R.sub.1 and R.sub.2 are as defined in the description, or salts thereof, the novel compounds of formula (I), and the preparation thereof. The compounds of formula (I) have valuable pharmacological properties and are alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, this receptor also being known as the quisqualate receptor. Furthermore, the compounds of formula (I) are non-competitive N-methyl-D-aspartate (NDMA) receptor antagonists, and particularly NMDA receptor glycine modulation site ligands.

Abstract: A compound of formula ##STR1## wherein R is a group of formula ##STR2## R.sub.1 is alkyl; and Ar is optionally substituted aryl.

Abstract: Compounds of formula (I): ##STR1## wherein R is a polyfluoroalkoxy or polyfluoroalkyl radical and R.sub.1 is a hydrogen atom and R.sub.2 is a hydroxyl radical, or R.sub.1 is a hydroxyl radical and R.sub.2 is a hydrogen atom, salts thereof, the preparation of said compounds, and drugs containing same.

Abstract: A transgenic rabbit expressing a protein capable of interfering with dyslipoproteinaemia-related diseases, a method of preparing the same, and its use as an animal model, are disclosed. Specifically, a transgenic rabbit expressing high levels of Apo-AI, is disclosed.

Abstract: A method for preparing streptogramins of the formula (I): ##STR1## wherein R.sub.1 is methyl or ethyl, R.sub.2 is H and X and Y together form an oxo radical, or R.sub.1 is ethyl, R.sub.2 and X are H and Y is H or OH, or else R.sub.1 is ethyl, R.sub.2 is OH and X and Y together form an oxo radical, by demethylation of a synergistin derivative of the formula (II): ##STR2## wherein R.sub.1, R.sub.2, X and Y are as defined above, by means of a treatment with a periodate in an acetic medium, followed by a treatment in an aqueous medium.

Abstract: A novel method for preparing vectors derived from adeno-associated viruses (AAV), cells used therefor, and the use of the resulting vectors, particularly in gene and/or cell therapy, are disclosed.

Abstract: The compounds of formula (I) ##STR1## wherein R, R.sub.1 and R.sub.2 are defined in the disclosure, and salts thereof.The compounds of formula (I) are non-competitive N-methyl-D-asparate (NMDA) receptor antagonists, particularly NMDA receptor glycine modulation site ligands, and are alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, this receptor is also known as the quisqualate receptor.

Abstract: Streptogramine derivatives of general formula (I) below, wherein the radical R.sub.1 is a methyl or ethyl radical, the radical R.sub.2 is a bromine or chlorine atom, or is an alkenyl radical with 3 to 5 carbon atoms when R.sub.3 and R.sub.4 are methyl, and one of R.sub.3 and R.sub.4 is a hydrogen atom or a methyl radical and the other is a methyl radical are disclosed. The streptogramine derivatives of general formula (I) have particularly useful antibacterial properties, and may be used in combination with a pristinamycin II derivative.

Abstract: This invention relates to taxoids of the formula (I): a method for preparing these taxoids, and pharmaceutical compositions containing them. In formula (I), R is alkyl radical (1-6 carbon atoms), alkenyl (2-6 carbon atoms), alkynyl (2-6 carbon atoms), cycloalkyl (3-6 carbon atoms), cycloalkenyl (4-6 carbon atoms), phenyl, unsaturated heterocyclyl containing from 5 to 6 links, Z is a hydrogen atom or a radical of formula (II): ##STR1## wherein R.sub.1 is an optionally substituted benzoyl radical, thenoyl radical, furoyl radical, or a radical R.sub.2 --O--CO-- in which R.sub.2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, optionally substituted phenyl or heterocyclyl, and R.sub.3 is an alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, naphthyl or aromatic heterocyclic radical. The taxoids of formula (I) in which Z is a radical of formula (II) have remarkable antitumoral and antileukemic properties.

Abstract: Compounds of formula (I): ##STR1## wherein R.sub.3 and R.sub.4, taken together with the carbon atom to which they are attached, form (a) a 2- or 3-pyrrolidine ring, a 2- or 4-piperidine ring or a 2-azacycloheptane ring, said rings being optionally substituted at the nitrogen atom by an alkyl, --CHO, --COOR.sub.11, --CO--alk--COOR.sub.6, --CO--alk--NR.sub.6 R.sub.12, --CO--alk--CONR.sub.6 R.sub.8, --CO--COOR.sub.6, --CO--CH.sub.2 --O--CH.sub.2 --COOR.sub.6, --CO--CH.sub.2 --S--CH.sub.2 --COOR.sub.6, --CO--CH.dbd.CH--COOR.sub.6, CO--alk, --CO--Ar", --CO--alk--Ar", --CO--NH--Ar", --CO--NH--alk--Ar", --CO--Het, --CO--alk--Het, --CO--NH--Het, --CO--NH--alk--Het, --CO--NH.sub.2, --CO--NH--alk, --CO--N(alk)alk', --CS--NH.sub.2, --CS--NH--alk, --CS--NH--Ar", --CS--NH--Het, --alk--Het, --alk--NR.sub.6 R.sub.8, --alk--COOR.sub.6, --alk--CO--NR.sub.6 R.sub.8, --alk--Ar", --SO.sub.2 --alk or --SO.sub.

Abstract: Nanoparticles are prepared by dissolving a poly(ethylene oxide) and/or poly(propylene oxide) polylactic copolymer in an organic solvent followed by formation of nanoparticles by mixing the solution containing the polymer with an aqueous solution and by precipitation, without using an additional colloidal protective agent or by microfluidization and solvent evaporation. Nanoparticles prepared by this method are disclosed.

Abstract: Compounds of formula (1) ##STR1## wherein either R is C.dbd.R.sub.3, C(R.sub.4)R.sub.5 or CH--R.sub.6, R.sub.1 and R.sub.2 are hydrogen, halogen, alkyl, alkoxy, amino, acylamino, --NH--CO--NH--Ar, --N.dbd.CH--N(alk)alk', nitro, cyano, phenyl, imidazolyl or SO.sub.3 H, R.sub.3 is oxygen, NOH, NO-alk-COOK or CH--R.sub.7, R.sub.4 is alkyl, -alk-Het or alk-Ar, R.sub.5 is alkyl, -alk-Het or -alk-Ar, or C(R.sub.4)R.sub.5 is cycloalkyl, R.sub.6 is hydroxy, alkyl, NR.sub.8 R.sub.9, -alk-OH, -alk-NR.sub.8 R.sub.9, -alk-Ar or -alk-Het, R.sub.7 is hydroxy, alkyl, phenyl, -alk-Ar, -alk-Het, NR.sub.10 R.sub.11 or a heterocyclic ring, R.sub.8 and R.sub.9 are alkyl, or R.sub.8 is hydrogen and R.sub.9 is hydrogen or alkyl, --COR.sub.12, --CSR.sub.30 or --SO.sub.2 R.sub.13, R.sub.10 and R.sub.11 are alkyl or cycloalkyl, R.sub.12 is alkyl, cycloalkyl, phenyl, --COO-alk, --CH.sub.2 --COOX, --CH.sub.2 NH.sub.2, --NH-alk, --NH--Ar, --NH.sub.2 or --NH-Het, R.sub.13 is alkyl or phenyl, R.sub.30 is --NH-alk, --NH--Ar, --NH.sub.

Abstract: The invention provides new compositions containing taxane derivatives, consisting of solutions of such derivatives in a solvent mixture composed of ethanol and polysorbate. These compositions are used to prepare perfusions.

Abstract: This invention relates to a process for the preparation of 7-hydroxy taxanes of general formula (I) from 7-trialkylsilyl taxanes of general formula (II), wherein R.sub.1 is hydrogen, alkoxy, acyloxy, or alkoxyacetoxy, and Z is a hydrogen atom or a radical of general formula (III), wherein R.sub.2 is an optionally substituted benzyl radical or an R'.sub.2 --O--CO-- radical wherein R'.sub.2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, optionally substituted phenyl or heterocyclyl radical, R.sub.3 is an aromatic alkyl, alkenyl, alkynyl, cycloalyl, phenyl, naphthyl or heterocyclyl radical and either R.sub.4 is a hydrogen atom and R.sub.5 is a hydroxyl function protecting group, or R.sub.4 and R.sub.5 together form a saturated 5- or 6-membered heterocylic ring. In general formula (II), each R, which are the same or different, is an alkyl radical optionally substituted by a phenyl radical.

Abstract: The invention is directed to a novel compound of formula ##STR1## in which R is a hydroxyl, alkyloxy, phenylalkyloxy or --NH--CH.sub.2 --COOH radical, R' and R" are identical and are each a hydroxy or methoxy radical and R'" represents a hydrogen, bromine, chlorine or iodine atom or a nitro radical. The invention is also directed to the salts of said compounds and their use.